Myopia Control News Today

Readers discuss why every district health centre should provide basic eye health services, the effectiveness of the tobacco tax, and the decline in politeness.

Michigan Contact Lens Introduces New Myopia Control Center

CooperVision, a global leader in myopia management, will host its coveted 3rd Asia Pacific Myopia Management Symposium (APMMS) at Marriott Taipei on 10 December 2023 in Taiwan region. In partnership with Universal Eye Center, the premier hybrid event will serve as a key platform in bringing together internationally renowned eye care professionals under one roof, as they discuss the rising prevalence of myopia in the Asia Pacific region and new interventions available to manage the disease.

Newtown Township, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Newtown Township, Pennsylvania - The Myopia Management Center of Excellence is currently accepting...

Kuala Lumpur: In conjunction with World Sight Day 2023, Focus Point Vision Care Group Sdn Bhd (Focus Point), the leading optical chain in Malaysia is hosting a week-long roadshow at Centre Court, Ground Floor, Mid Valley Megamall from 9th to 15th October 2023 with the theme “Love Your Eyes, Embrace Your Future”.

- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected...

“Everyone has noticed that it seems like the kids are becoming nearsighted faster than they used to,” says Dr. Grace Prakalapakorn at the Duke Eye Center.

“Everyone has noticed that it seems like the kids are becoming nearsighted faster than they used to,” says Dr. Grace Prakalapakorn at the Duke Eye Center.

SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the execution of a collaborative research agreement between Kubota Vision and China...

Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years, according to a randomized controlled trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and funded by the National Eye Institute (NEI). The trial aimed to identify an effective way to manage this leading and increasingly common cause of refractive error, which can cause serious uncor...